Jeito Capital Closes Record $1.2 Billion Independent European Biopharma Fund
Jeito Capital closed its Jeito II fund at 1 billion euros, approximately $1.2 billion. This represents the largest raise for an independent European fund focused on the biopharma sector. The Paris-based firm plans to support 15 to 20 clinical-stage drugmakers. Individual investments will reach up to 150 million euros. The fund targets companies in Europe and North America developing therapies for high unmet medical needs.
Jeito launched in 2020 and closed its first fund of 534 million euros in 2021. The firm already deployed capital from the new fund. It participated in a $197 million Series A round for Alveus Therapeutics in February. Jeito focuses on therapeutic areas with high demand. These include oncology, obesity, and autoimmune conditions. The firm previously recorded successful exits through the acquisitions of Neogene, EyeBio, and Hi-Bio.
Key Takeaways
- Jeito Capital closed its second fund at 1 billion euros, the largest for an independent European biopharma fund.biopharmadive.combusinesswire.comfiercebiotech.com
- The fund will invest in 15 to 20 clinical-stage companies with individual checks up to 150 million euros.biopharmadive.com
- Jeito has already deployed capital from the new fund into Alveus Therapeutics.biopharmadive.com
- The firm's previous exits include the acquisitions of Neogene, EyeBio, and Hi-Bio.biopharmadive.com
Affected Companies
Sources
Biotech Investor Jeito Capital Raises $1.2 Billion for New Biopharma Fund
BioPharma Dive
“Reported that Jeito Capital closed a $1.2 billion fund to support 15 to 20 clinical-stage drugmakers with individual investments up to 150 million euros.”
Jeito Capital Hits Record $1.2 Billion (‑1 Billion) Close for Jeito II Fund
BusinessWire
“According to this source, the Jeito II fund reached a record 1 billion euro close to drive therapeutic innovation.”
Jeito hails $1.2B 'largest raise ever' for independent biopharma-focused European fund
FierceBiotech
“Reported that Jeito Capital described its $1.2 billion raise as the largest ever for an independent European fund focused on biopharma.”